GeoVax Labs, Inc. (Nasdaq-CM: GOVX, GOVXW) is a clinical-stage biotechnology company with a robust pipeline of human vaccines and immunotherapies to address unmet medical needs in cancer and infectious disease.
Our products are based upon a novel patented Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based vaccine platform. On this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens within (in vivo) the person receiving the vaccine.
As I sit here, eating my butter sandwich (thanks $ONTX) I wonder why in the hell would I put myself through such pain again? Ah, it's because it's part of the game.
On September 29th, they closed the offering of 2,560,000 units of its common stock, about $12.8m at $5 a share. The president, David Dodd bought $409,350 of shares priced at $5. It now down 37% since then. Do you honestly think he'd buy that many shares for a loss?
- Unusually high volume in October.What gives? The chart looks smoother than the brains of Hindenburg Research. Should the price remain stagnant during massive buying volume? I don't think so. That tells me something a little suspicious is going on, but I'll roll with it. They have a pipeline of products coming into Q4, and they are also focusing their efforts into the COVID theme.
Link to their COVID efforts initiated in January can be found here: https://www.geovax.com/technology-pipeline/infectious-diseases
They also talk about focusing efforts on curing HIV/AIDS. I should take a long position to help my fantasy football team.
**Not a financial advisor. Articles are opinions only
Hounder Media Newsletter
Join the newsletter to receive the latest updates in your inbox.